May 24, 2000Wyeth Ayerst Laboratories
Recalls Meperidine HCL Injection
Davids, PA (SafetyAlerts) - The Food
and Drug Administration (FDA) today reported that Wyeth Ayerst Laboratories is conducting
a recall of Meperidine HCL Injection, USP, because of lack of assurance of sterility.
The Meperidine HCL Injection is a
prescription for relief of moderate to severe pain, for pre-operative medication, for
support on anesthesia, and for obstetrical analgesia.
The recall affects:
50 mg/mL in 30mL vial, NDC
#0008-0258-01 with the Lot numbers 4970174 EXP 11/00, 4980176 EXP 6/01, 4980216 EXP 7/01
or 4990104 EXP 2/02.
100 mg/mL in 20 mL vial, NDC
#0008-0259-0, with the Lot numbers 4970175 EXP 11/00, 4980213 EXP 6/01, 4980214 EXP 9/01,
4990084 EXP 3/02.
FDA stated in its report that
approximately 95,786 vials were distributed nationwide.
This ongoing Class II recall
was initiated by the company, by letter dated March 13, 2000. This is the first
public notice issued by the FDA.
Questions concerning this recall may
be directed to the FDA at 1-888-INFO-FDA.
FDA Recall #d-356/357-0
Notice of this product warning was
sent via email to SafeMail
subscribers May 24, 2000.
Safety Alerts compiles
comprehensive safety recall information for the United States. SafeMail is a free email
service to warn consumers of faulty products and contaminated foods. For complete
information regarding current recalls, past recalls and timely product warning
notification visit: www.safetyalerts.com.